“Appendix 3B New issue announcement, application for quotation of additional securities and agreement” has been released by Imagion Biosystems. Read Appendix 3B here.
The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials
September 4, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required